Inherited platelet disorders

Haemophilia

Volumn 18, Issue SUPPL.4, 2012, Pages 154-160

  Nurden, A T ^a   Freson, K ^b   Seligsohn, U ^c  

^a Ctr Geriatrie Ctr Hosp Univ B   (France)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c The Amalia Biron Research Institute of Thrombosis and Hemostasis   (Israel)

Author keywords

Bleeding syndromes; Diagnosis; Inherited disorders; Platelets; Treatment

Indexed keywords

AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 9; CONJUGATED ESTROGEN; DESMOPRESSIN; ELTROMBOPAG; GESTAGEN; GLYCOPROTEIN IB; HEPATITIS B VACCINE; INTEGRIN; INTEGRIN ALPHA2BETA3; MEDROXYPROGESTERONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROCOAGULANT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; ROMIPLOSTIM; THROMBOPOIETIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; ARTICLE; BERNARD SOULIER DISEASE; BLEEDING; BLOOD VESSEL INJURY; BONE MARROW; BONE MARROW TRANSPLANTATION; BREAKTHROUGH BLEEDING; CELL LINEAGE; CELL MATURATION; CELL ORGANELLE; CELL STRUCTURE; CHEDIAK HIGASHI SYNDROME; CLINICAL FEATURE; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; DISEASE SEVERITY; DNA SEQUENCE; DRUG MEGADOSE; ELECTRON MICROSCOPY; EPIGENETICS; EXOME; FAMILIAL THROMBOCYTOPENIA; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; FRAMESHIFT MUTATION; GENE; GENETIC ASSOCIATION; GLANZMANN DISEASE; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOSTASIS; HOT FLUSH; HUMAN; HYPONATREMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LUNG EMBOLISM; MEGAKARYOCYTE; MENORRHAGIA; MISSENSE MUTATION; MYH9 GENE; NONSENSE MUTATION; OCULAR ALBINISM; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCOTT SYNDROME; SEIZURE; TACHYCARDIA; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; URETER DISEASE; WISKOTT ALDRICH SYNDROME;

BLOOD COAGULATION DISORDERS, INHERITED; BLOOD PLATELET DISORDERS; HUMANS; PLATELET MEMBRANE GLYCOPROTEINS; SIGNAL TRANSDUCTION;

EID: 84862893491     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02856.x     Document Type: Article

References (48)

1. Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, Minford A, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135: 606-33.
2. Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost 2011; 9: 76-91.
3. Hayward CP. Diagnostic evaluation of platelet function disorders. Blood Rev 2011; 25: 169-73.
4. Israels SJ, Kahr WH, Blanchette VS, Luban NL, Rivard GE, Rand ML. Platelet disorders in children: a diagnostic approach. Pediatr Blood Cancer 2011; 56: 975-83.
5. Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Wintger M, Machin S. British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155: 30-44.
6. Salles II, Feys HB, Iserbyt BF, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Inherited traits affecting platelet function. Blood Rev 2008; 22: 253-63.
7. Nurden P, Gobbi G, Nurden A, Enouf J, Youlyouz-Marfak I, Carubbi C, La Marca S, et al. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood 2010; 115: 2649-56.
8. Cattaneo M. The platelet P2Y12 receptor for adnosine diphosphate: congenital and drug-induced defects. Blood 2011; 117: 2102-12.
9. Watson S, Daly M, Dawood B, Gissen P, Makris M, Mundell S, Wilde J, Mumford A. Phenotypic approaches to gene mapping in platelet function disorders. Identification of new variant of P2Y12, TxA2 and GPVI receptors. Hämostaseologie 2010; 30: 29-38.
10. Van Geet C, Izzi B, Labarque V, Freson K. Human platelet pathology related to defects in the G-protein signaling cascade. J Thromb Haemost 2009; 7 (Suppl. 1): 282-6.
11. Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: Clinical and molecular genetics. Annu Rev Genomics Hum Genet 2008; 9: 359-86.
12. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, Zivony-Elboum Y, Gumruk F, Cetin M, Khayat M, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules. Nat Genet 2011; 43: 732-4.
13. Albers CA, Cvejic A, Favier R, Bouwmans EE, Alessi MC, Bertone P, Jordan G, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet 2011; 43: 735-7.
14. Kahr WH, Hinckley J, Li L, Schwertz H, Christensen H, Rowley JW, Pluthero FG, Urban D, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet 2011; 43: 738-40.
15. Paterson AD, Rommens JM, Bharaj B, Blavignac J, Wong I, Diamandis M, Waye JS, et al. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood 2010; 115: 1264-6.
16. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 dfefects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011; 118: 5996-6005.
17. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin αIIbβ3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2006; 112: 3011-25.
18. Mor-Cohen R, Rosenberg N, Landau M, Lahav J, Seligsohn U. Specific cysteines in β3 are involved in disulfide bond exchange-dependent and -independent activation of αIIbβ3. J Biol Chem 2008; 283: 19235-44.
19. Nurden AT, Pillois XA, Fiore M, Heilig R, Nurden P. Macrothrombocytopenias caused by mutations in the genes encoding the αIIbβ3 integrin. Semin Thromb Haemost 2011; 37: 696-706.
20. Van de Vijver E, De Cuper IM, Gerritis AJ, Verhoeven AJ, Seeger K, Guttiérrez L, van den Berg TK, Kuijpers TW. Defects in Glanzmann thrombasthenia and LAD-III syndrome: the role of β1 and β3 in platelet adhesion to collagen. Blood 2012; 119: 583-6.
21. Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010; 468: 834-8.
22. Millikan PD, Balamohan SM, Raskind WH, Kacena MA. Inherited thrombocytopenia due to GATA-1 mutations. Semin Thromb Haemost 2011; 37: 682-9.
23. Kaur G, Jalagadugula G, Mao G, Rao AK. RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. Blood 2010; 115: 3128-35.
24. Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-inherited thrombocytopenia. Br J Haematol 2011; 154: 161-74.
25. Nurden P, Debili N, Coupry I, Bryckaert M, Youlyouz-Marfak I, Solé G, Pons AC, et al. Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood 2011; 118: 5928-37.
26. Noris P, Perrotta S, Seri M, Pecci A, Gnan C, Loffredo G, Pujol-Moix N, et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood 2011; 117: 6673-80.
27. Latger-Cannard V, Hoaru M, Salignac S, Baumgart D, Nurden P, Lecompte T. Mean platelet volume: comparison of three analysers towards standardization of platelet morphological phenotype. Int J Lab Hematol 2012; 34: 300-10.
28. Konopatskaya O, Gilio K, Harper MT, Zhao Y, Cosemans JM, Karim ZA, Whiteheart SW, et al. PKCα regulates platelet granule secretion and thrombus formation in mice. J Clin Invest 2009; 119: 399-407.
29. Peines I, Hagedorn I, Gupta S, May F, Chakarova L, van Hangel J, Offermanns S, et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood 2012; 119: 1054-63.
30. Freson K, Labarque V, Thys C, Wittevrongel C, Van Geet C. What's new in using platelet research? To unravel thrombopathies and other human disorders. Eur J Pediatr 2007; 166: 1203-10.
31. García A. Clinical proteomics in platelet research: challenges ahead. J Thromb Haemost 2010; 8: 1784-5.
32. Jones CI, Bray S, Garner SF, Stephens J, de Bono B, Angenent WG, Bentley D, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 2009; 114: 1405-16.
33. Gieger C, Radhakrishnan A, Cvejic A, Tang W, Porcu E, Pistis G, Serbanovic-Canic J, et al. New gene functions in megakaryopoiesis and platelet formation. Nature 2011; 480: 201-8.
34. Freson K, Izzi B, Van Geet C. From genetics to epigenetics in platelet research. Thromb Res 2012; 129: 325-9.
35. Castermans D, Volders K, Crepel A, Backx L, De Vos R, Freson K, Meulemans S, et al. SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense-core vesicles. Hum Mol Genet 2010; 19: 1368-78.
36. Marian AJ. Medical DNA sequencing. Curr Opin Cardiol 2011; 26: 175-80.
37. Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011; 17: e858-69.
38. Peitsidis P, Datta T, Pafilis I, Otomewo O, Tuddenham EG, Kadir RA. Bernard-Soulier syndrome in pregnancy: a systematic review. Haemophilia 2010; 16: 584-91.
39. Fiore M, Firah N, Pillois X, Nurden P, Heilig R, Nurden A. A natural history of platelet antibody formation against αIIbβ3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia 2012; 18: e201-9.
40. Cattaneo M. Desmopressin in the treatment of patients with defects of platelet function. Haematologica 2002; 87: 1122-4.
41. Coppola A, Di Minno G. Desmopressin in inherited disorders of platelet function. Haemophilia 2008; 14(Suppl 1): 31-9.
42. Poon MC, D'Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2: 1096-103.
43. Poon MC. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev 2007; 21: 223-36.
44. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
45. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired αIIbβ3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003; 101: 1864-70.
46. Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103: 1720-7.
47. Alamelu J, Liesner R. Modern management of severe platelet function disorders. Br J Haematol 2010; 149: 813-23.
48. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Diez IA, Sewey RA, Böhm M, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. New Engl J Med 2010; 363: 1918-27.